Unlock AI-driven, actionable R&D insights for your next breakthrough.

Ethylene Dichloride Pharmaceutical Intermediate Modified Material: Comprehensive Analysis Of Production, Purification, And Advanced Applications

JUN 8, 202663 MINS READ

Want An AI Powered Material Expert?
Here's PatSnap Eureka Materials!
Ethylene dichloride (1,2-dichloroethane, EDC) serves as a critical pharmaceutical intermediate and versatile chemical building block in modern synthetic chemistry. This chlorinated hydrocarbon exhibits exceptional reactivity profiles that enable its transformation into vinyl chloride monomers, pharmaceutical precursors, and specialty chemical intermediates through catalytic dehydrochlorination, oxychlorination, and thermal cracking pathways 1,3,5. Recent advances in sustainable production routes, including bio-based monoethylene glycol conversion processes, have expanded the commercial viability of ethylene dichloride while addressing environmental concerns associated with traditional chlorination methods 8. Understanding the molecular engineering, purification strategies, and catalytic modification techniques for ethylene dichloride pharmaceutical intermediate modified materials is essential for researchers developing next-generation synthetic routes and optimizing process economics in pharmaceutical manufacturing.
Want to know more material grades? Try PatSnap Eureka Material.

Molecular Structure And Chemical Properties Of Ethylene Dichloride Pharmaceutical Intermediate Modified Material

Ethylene dichloride (C₂H₄Cl₂, CAS 107-06-2) possesses a molecular weight of 98.96 g/mol and exhibits a symmetric structure with two chlorine atoms attached to adjacent carbon atoms. The compound demonstrates a boiling point of 83.5°C at atmospheric pressure and a melting point of -35.7°C, making it a volatile liquid under standard conditions 1,2. The density of pure ethylene dichloride ranges from 1.235 to 1.253 g/cm³ at 20°C, depending on the presence of trace impurities and water content 11.

The chemical reactivity of ethylene dichloride stems from the polarized C-Cl bonds (bond dissociation energy approximately 338 kJ/mol), which facilitate nucleophilic substitution reactions and elimination pathways critical for pharmaceutical intermediate synthesis. The compound exhibits limited miscibility with water (8.7 g/L at 20°C) but demonstrates complete miscibility with most organic solvents including alcohols, ethers, and aromatic hydrocarbons 2,10.

Key physical properties relevant to pharmaceutical intermediate applications include:

  • Vapor Pressure: 87 mmHg at 25°C, enabling efficient distillation-based purification 11
  • Dielectric Constant: 10.36 at 25°C, supporting polar reaction mechanisms 1
  • Viscosity: 0.79 cP at 25°C, facilitating liquid-phase processing 12
  • Heat of Vaporization: 32.0 kJ/mol, critical for thermal management in production systems 1,12

The presence of trace unsaturated impurities such as trichloroethylene and benzene (typically 50-500 ppm in crude streams) significantly impacts downstream pharmaceutical applications, necessitating advanced purification protocols 2,11.

Production Methodologies For Ethylene Dichloride Pharmaceutical Intermediate Modified Material

Direct Chlorination Routes And Process Optimization

The primary industrial route for ethylene dichloride production involves the exothermic liquid-phase chlorination of ethylene (C₂H₄ + Cl₂ → C₂H₄Cl₂, ΔH = -218 kJ/mol) conducted in circulating reaction media maintained below the vaporization point of the product 1,10. Modern production facilities employ reaction temperatures between 40-80°C and pressures of 1.5-3.0 bar to maximize selectivity while minimizing byproduct formation 1,12.

The reaction mechanism proceeds through a radical chain process initiated by trace iron catalysts (typically 10-50 ppm Fe³⁺), which accelerate chlorine activation without promoting over-chlorination to trichloroethane 4,10. Advanced reactor designs incorporate multiple chlorine injection points distributed along the reaction zone to maintain optimal Cl₂/C₂H₄ molar ratios of 1.02-1.05, ensuring >99.5% ethylene conversion while limiting chlorinated byproducts to <0.3 wt% 10,12.

Heat management represents a critical challenge in direct chlorination, with modern systems utilizing thermosyphon circulation loops coupled to external shell-and-tube heat exchangers to maintain isothermal conditions (±2°C) throughout the 5,000-50,000 L reaction vessels 12. The exothermic heat is recovered for downstream distillation operations, achieving overall thermal efficiencies exceeding 92% 1,10.

Oxychlorination Pathways And Catalyst Systems

Oxychlorination of ethylene (C₂H₄ + 2HCl + ½O₂ → C₂H₄Cl₂ + H₂O) provides an alternative route that consumes hydrogen chloride byproducts from vinyl chloride production, creating integrated manufacturing loops 3,7. This process operates at elevated temperatures (220-260°C) over fluidized-bed catalysts comprising copper chloride (5-8 wt% CuCl₂) supported on γ-alumina or silica carriers with surface areas of 150-250 m²/g 3,7.

The oxychlorination reaction generates ethyl chloride (C₂H₅Cl) as a significant byproduct (3-8 wt% of total product), which must be separated and catalytically cracked to recover ethylene and hydrogen chloride 3. Advanced process configurations fractionate the reactor effluent into an ethylene dichloride-rich stream (containing <50% of total ethyl chloride) and an ethyl chloride-rich stream (with EDC + vinyl chloride content <30 wt% of ethyl chloride mass) to optimize downstream cracking efficiency 3.

Catalyst deactivation through copper sintering and chloride volatilization limits bed lifetimes to 18-36 months, necessitating periodic regeneration cycles involving oxidative treatment at 400-450°C followed by re-chlorination 3,7. Emerging zeolite-supported catalysts (Cu-ZSM-5, Cu-Beta) demonstrate enhanced stability and selectivity, reducing ethyl chloride formation to <2 wt% while extending operational lifetimes beyond 48 months 9.

Sustainable Production From Bio-Based Feedstocks

Recent innovations have established viable routes for producing ethylene dichloride from renewable monoethylene glycol (MEG), addressing sustainability concerns in pharmaceutical intermediate supply chains 8. The process involves catalytic dehydration of MEG to ethylene oxide followed by hydrochlorination, or direct chlorination of bio-derived ethylene obtained through MEG dehydration 8.

Techno-economic analyses indicate that bio-based ethylene dichloride production achieves carbon footprint reductions of 40-65% compared to fossil-derived routes when utilizing MEG from cellulosic or CO₂-based synthesis 8. However, production costs remain 15-25% higher due to feedstock pricing and additional purification requirements for bio-derived intermediates 8. Ongoing catalyst development focusing on selective MEG chlorination using supported metal halide systems (ZrCl₄/SiO₂, TiCl₄/Al₂O₃) aims to improve process economics through single-step conversion pathways 8.

Advanced Purification And Separation Technologies For Pharmaceutical-Grade Ethylene Dichloride

Extractive Distillation For Unsaturated Impurity Removal

Pharmaceutical-grade ethylene dichloride requires stringent purity specifications (>99.9% with unsaturated compounds <10 ppm) that cannot be achieved through conventional distillation due to azeotrope formation with trichloroethylene (b.p. 87°C) and close-boiling chlorinated impurities 2,11. Extractive distillation employing high-boiling chloroalkene solvents, particularly perchloroethylene (tetrachloroethylene, b.p. 121°C), enables effective separation by selectively increasing the relative volatility of ethylene dichloride 2.

The process operates in distillation columns with 40-60 theoretical stages at pressures of 1.2-1.8 bar, with perchloroethylene introduced at a solvent-to-feed ratio of 2.5-4.0 (mass basis) 2. The overhead product achieves ethylene dichloride purities exceeding 99.95% with trichloroethylene content reduced to <5 ppm, while the bottoms stream containing perchloroethylene and concentrated impurities is regenerated in a secondary column 2. Solvent losses are maintained below 0.1 wt% through efficient condenser design and vapor recovery systems 2.

Alternative extractive agents including hexachlorobutadiene and chlorinated cyclopentadienes have been evaluated, but perchloroethylene remains preferred due to its optimal selectivity (α = 1.8-2.2 for EDC/trichloroethylene), thermal stability, and commercial availability 2,19.

Azeotropic Distillation For Light Impurity Separation

Carbon tetrachloride (b.p. 76.7°C) and chloroform (b.p. 61.2°C) form minimum-boiling azeotropes with ethylene dichloride that complicate purification 11. Specialized distillation protocols maintain reflux compositions above 51.5 mole% chloroform to shift the azeotropic composition and enable overhead removal of light chlorinated impurities while minimizing ethylene dichloride losses to <0.5 wt% 11.

The process employs distillation columns with 25-35 theoretical stages operating at reduced pressures (0.3-0.5 bar) to lower operating temperatures and prevent thermal degradation 11. Reflux ratios of 8-12:1 are maintained in the upper section to achieve the critical chloroform concentration, while reboiler duties are carefully controlled to prevent localized overheating that promotes dehydrochlorination 11,15.

Advanced column internals including structured packing (Mellapak 250Y, Montz B1-300) provide high separation efficiency (HETP 0.3-0.4 m) while minimizing pressure drop and reducing energy consumption by 20-30% compared to conventional tray designs 11.

Fouling Prevention In Distillation Systems

Thermal degradation of ethylene dichloride during distillation generates polymeric residues and carbonaceous deposits that foul reboiler surfaces and column internals, reducing separation efficiency and necessitating frequent shutdowns 15. The fouling mechanism involves radical-initiated polymerization of vinyl chloride formed through trace dehydrochlorination, catalyzed by acidic sites and metal contaminants 15.

Effective fouling prevention employs specialized additive packages comprising 15:

  • Polyacrylate Dispersants (2-15 wt% of additive): Oil-soluble polyacrylate or polymethacrylate esters with C₄-C₂₂ alcohol radicals containing 0.1-25 mole% amino alcohol ester groups that disperse nascent polymer particles and prevent surface adhesion
  • Phenylene Diamine Antioxidants (20-40 wt% of additive): Compounds with the general structure C₆H₄(NHR)₂ where R groups are H, C₁-C₂₀ alkyl, aryl, alkaryl, or aralkyl substituents that scavenge radical intermediates and inhibit polymerization initiation
  • Heavy Aromatic Solvent (balance): High-boiling aromatic carriers (b.p. 280-320°C) that ensure uniform additive distribution and thermal stability

Additive dosing rates of 50-200 ppm (based on ethylene dichloride feed) reduce fouling rates by 75-90%, extending operational campaigns from 3-6 months to 12-24 months between cleanings 15. The additives do not adversely affect downstream vinyl chloride polymerization when residual concentrations are maintained below 5 ppm in purified ethylene dichloride 15.

Catalytic Modification And Conversion Pathways For Pharmaceutical Intermediate Applications

Dehydrochlorination To Vinyl Chloride And Acetylene

Thermal cracking of ethylene dichloride to vinyl chloride (C₂H₄Cl₂ → C₂H₃Cl + HCl) represents the primary industrial conversion pathway, conducted at 480-520°C in tubular reactors with residence times of 10-25 seconds 6,18. Conventional thermal cracking achieves 50-60% single-pass conversion with vinyl chloride selectivity of 98-99.5%, requiring extensive recycle loops and energy-intensive separation systems 6.

Advanced catalytic dehydrochlorination processes employ noble metal catalysts (0.5-2.0 wt% Pt, Pd, or Rh) supported on activated carbon to enable lower reaction temperatures (250-400°C) while maintaining comparable conversion rates 5. The catalytic route operates in the presence of hydrogen gas (H₂/EDC molar ratio 0.5-2.0) which suppresses coke formation and maintains catalyst activity 5. Pilot-scale demonstrations have achieved 65-75% single-pass conversion at 320°C with vinyl chloride selectivity exceeding 99.2%, reducing energy consumption by 30-40% compared to thermal processes 5.

For specialized pharmaceutical applications requiring acetylene intermediates, high-temperature pyrolysis of ethylene dichloride at 800-1000°C in the presence of steam diluent (steam/EDC volume ratio 8-15:1) generates acetylene with yields of 35-50% alongside vinyl chloride (20-30% yield) 13. Contact times of 1-6 seconds in ceramic-lined reactors minimize secondary reactions, while rapid quenching to <200°C within 0.1-0.2 seconds preserves product selectivity 13.

Catalytic Oxyhalogenation For Pharmaceutical Precursor Synthesis

Monosubstituted saturated hydrocarbons undergo selective oxyhalogenation to saturated dihalohydrocarbons over zeolite-supported variable valence metal catalysts at 180-350°C 9. This transformation enables direct conversion of ethyl chloride to ethylene dichloride (C₂H₅Cl + ½O₂ + HCl → C₂H₄Cl₂ + H₂O) with selectivity exceeding 92% when employing Cu-ZSM-5 or Cu-Beta catalysts (3-6 wt% Cu loading) 9.

The catalytic mechanism involves oxidative activation of the C-H bond adjacent to the existing chlorine substituent, followed by chlorination and elimination to form the vicinal dichloride product 9. Reaction conditions of 220-280°C, 2-4 bar pressure, and O₂/HCl/ethyl chloride molar ratios of 0.3-0.5:1.0-1.5:1.0 optimize selectivity while minimizing over-oxidation to chlorinated aldehydes and acids 9.

This catalytic route provides an efficient method for upgrading ethyl chloride byproducts from oxychlorination processes, achieving overall ethylene-to-ethylene dichloride yields of 96-98% in integrated production schemes 3,9.

Nucleophilic Substitution Pathways For Pharmaceutical Intermediate Synthesis

Ethylene dichloride serves as a versatile electrophilic building block for pharmaceutical intermediate synthesis through nucleophilic substitution reactions with nitrogen, oxygen, and sulfur nucleophiles 16,17. The vicinal dichloride structure enables sequential or simultaneous displacement reactions to generate diverse functionalized products.

Alkaline dehydrochlorination using inorganic bases (NaOH, KOH, Ca(OH)₂) in alcoholic media produces vinyl chloride under mild conditions (60-100°C) suitable for small-scale pharmaceutical applications 16,17. The process employs monohydric aliphatic or cycloaliphatic alcohols (C₄-C₈) in which the inorganic alkali exhibits partial solubility, enabling controlled reaction rates and high selectivity 16. Typical conditions involve heating ethylene dichloride with equimolar alkali in n-butanol, amyl alcohol, or cyclohexanol under reflux (100-140°C) for 2-6 hours, achieving vinyl chloride yields of 85-95% 16.

For pharmaceutical intermediates requiring intact ethylene dichloride scaffolds, controlled monosubstitution reactions with amine, thiol, or alkoxide nucleophiles proceed selectively at 40-80°C in polar aprotic solvents (DMF, DMSO, NMP) 16. The remaining chlorine substituent provides a handle for subsequent functionalization, enabling convergent synthetic strategies for complex pharmaceutical targets.

Applications Of Ethylene Dichloride Pharmaceutical Intermediate Modified Material In Drug Synthesis

Synthesis Of Nitrogen-Containing Pharmaceutical Intermediates

Ethylene dichloride serves as a key C₂ building block for constructing nitrogen heterocycles and

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
STAUFFER CHEMICAL COMPANYLarge-scale pharmaceutical intermediate manufacturing requiring continuous ethylene dichloride production with optimized energy recovery and temperature control in 5,000-50,000L reaction vessels.Ethylene Dichloride Production SystemUtilizes reaction heat for vaporization and rectification of circulating medium, achieving thermal efficiency exceeding 92% with thermosyphon circulation loops maintaining isothermal conditions within ±2°C.
PPG INDUSTRIES INC.Pharmaceutical-grade ethylene dichloride production requiring stringent purity specifications (<10 ppm unsaturated compounds) for drug synthesis and specialty chemical intermediate applications.EDC Extractive Distillation Purification SystemEmploys perchloroethylene solvent to achieve >99.95% ethylene dichloride purity with trichloroethylene reduced to <5 ppm through 40-60 stage distillation at selectivity α=1.8-2.2.
DOW CHEMICAL COMPANYClosed-loop vinyl chloride manufacturing facilities requiring efficient byproduct recycling and hydrogen chloride utilization for pharmaceutical intermediate production.Integrated Oxychlorination-Cracking ProcessConverts ethyl chloride byproducts to ethylene dichloride with >92% selectivity using Cu-ZSM-5 catalysts, achieving overall ethylene-to-EDC yields of 96-98% in integrated production schemes.
AKZO NOBEL N.V.Pharmaceutical intermediate synthesis requiring lower-temperature vinyl chloride production with reduced thermal degradation and enhanced process safety for drug precursor manufacturing.Catalytic Dehydrochlorination SystemNoble metal catalysts (0.5-2.0 wt% Pt/Pd/Rh) on activated carbon enable 65-75% single-pass conversion at 320°C with >99.2% vinyl chloride selectivity, reducing energy consumption by 30-40%.
NALCO CHEMICAL COMPANYContinuous pharmaceutical-grade ethylene dichloride purification systems requiring extended operation cycles and prevention of polymeric deposits in distillation reboilers and column internals.EDC Distillation Fouling Prevention AdditivePolyacrylate dispersant formulation at 50-200 ppm dosing reduces fouling rates by 75-90%, extending operational campaigns from 3-6 months to 12-24 months between cleanings.
Reference
  • Process for preparing ethylene dichloride
    PatentInactiveUS4347391A
    View detail
  • Purification and recovery of ethylene dichloride
    PatentInactiveUS4333799A
    View detail
  • Process for producing ethylene dichloride
    PatentInactiveCA1299203C
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png